The latest price target for Krystal Biotech (NASDAQ:KRYS) was reported by Citigroup on May 16, 2025. The analyst firm set a price target for $155.00 expecting KRYS to rise to within 12 months (a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter. I just am not sure if I should be buying Krystal Biotech at current ...

Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $212 from $208 and keeps a Buy rating on the shares post the Q3 report. The firm says the Vyjuvek launch remains strong.

In a welcome move, Krystal Biotech saw its Relative Strength ... Profits And Minimize Losses IBD's unique rating measures share price movement with a 1 (worst) to 99 (best) score.

HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Chardan Capital increased their price target ...

Based on the one-year price targets offered by 10 analysts, the average target price for Krystal Biotech Inc (NASDAQ:KRYS) is $217.20, with a high estimate of $245.00 and a low estimate of $195.00.

Krystal Integrated Services share price declined over 4% on Friday amid broader weakness in the Indian stock market. Krystal Integrated Services shares have dropped as much as 4.27% to a low of ...